查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1857407

抗血管內皮生長因子療法市場按產品類型、治療領域、給藥途徑、通路和最終用戶分類－2025-2032年全球預測

Anti-vascular Endothelial Growth Factor Therapeutics Market by Product Type, Therapeutic Area, Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，抗血管內皮生長因子療法市場將成長至 187.3 億美元，複合年成長率為 9.57%。

主要市場統計數據
基準年 2024 90.1億美元
預計年份：2025年 98.7億美元
預測年份：2032年 187.3億美元
複合年成長率 (%) 9.57%

簡單介紹抗 VEGF 療法的發展歷程以及影響現代視網膜照護的臨床和商業性因素。

抗血管內皮生長因子（VEGF）療法徹底改變了視網膜疾病的臨床治療，從實驗生技藥品發展成為治療威脅視力疾病的標準療法。這些藥物針對血管內皮生長因子通道，減少病理性新生血管形成和血管滲漏，從而穩定或改善許多患者的視力。隨著時間的推移，治療模式已從不頻繁且繁瑣的治療轉變為以患者為中心的治療方案，兼顧療效、安全性和給藥便利性。

臨床重點、技術進步和商業性壓力如何融合，正在重新定義視網膜護理的產品價值和護理服務模式

抗VEGF藥物領域正經歷著一場變革，這場變革是由臨床、技術和商業性力量的融合所驅動的。在臨床方面，人們越來越關注如何在不影響長期視覺效果的前提下減輕治療負擔，因此，能夠延長給藥間隔的藥物和劑型備受關注。在技​​術方面，製劑、分子設計和給藥裝置的逐步創新正在催生新的價值主張，這些價值提案的核心在於穩定性、無菌性和給藥效率。

美國近期關稅調整對生物眼科治療產品供應鏈韌性、籌資策略和分銷計劃的影響

美國近期關稅政策的變化和貿易政策調整，為包括抗VEGF藥物在內的生技藥品的全球供應鏈規劃和成本結構引入了新的變數。這些政策轉變正在影響策略採購決策，促使相關人員重新評估其生產佈局、區域供應冗餘和供應商多元化，以降低進口成本波動帶來的風險。製造商和經銷商已採取應對措施，探索陸上包裝、本地灌裝和包裝合作以及替代物流方案，以維持供應的連續性並保障利潤率。

將產品屬性、適應症、劑型、分銷管道和醫療保健環境與策略性採納槓桿聯繫起來的綜合細分分析

細分市場層面的動態揭示了價值實現的細微差別，這些差別因產品、適應症、給藥途徑、分銷管道和最終用戶環境而異。差異化的產品類型，例如阿柏西普、Bevacizumab單抗、布羅盧西珠單抗和雷珠單抗，會影響臨床定位、安全性討論和採購行為。每種分子的臨床特徵都會影響治療流程和支付方的優先排序。治療領域的細分，例如老齡化黃斑部病變、糖尿病黃斑部水腫、近視性脈絡膜新生血管和視網膜靜脈阻塞，有助於了解患者群體、給藥管道和預期治療進度，從而影響醫療服務提供者如何選擇藥物以平衡療效和臨床容量。

美洲、歐洲、中東和非洲以及亞太地區的區域動態和存取因素將影響招募和籌資策略。

美洲、歐洲、中東和非洲以及亞太地區的區域動態受不同的管理體制、醫療服務基礎設施和支付方環境的影響。在美洲，支付方的整合談判和垂直整合的醫療服務提供者體系影響著藥物配製和合約策略，而大型三級醫療中心和門診手術中心網路則決定著治療能力和病患吞吐量。同時，生物相似藥和仿單標示外用藥的監管政策的明朗化可能會改變競爭動態和採購方式。

傳統製造商、生物技術創新者和服務供應商之間既競爭又合作的動態，決定了產品差異化和市場進入的成功。

該領域的競爭動態源自於大型跨國製藥公司、眼科專家和生技創新者共同追求差異化的分子設計和遞送平台。同時，新參與企業力求透過延長保存期限、提高安全性以及提供基於工具的便利性來脫穎而出。此外，生物相似藥和替代生技藥品的研發也正在加速推進，迫使現有企業加強對生命週期策略、最佳化服務模式和實證醫學證據的投入，以捍衛其臨床地位。

對於製造商和醫療保健提供者而言，為實現持續推廣應用，切實可行的策略要務是協調臨床證據、配方、供應彈性和支付方參與。

產業領導者應優先考慮整合策略，將臨床差異化與營運執行和支付方互動結合。首先，應投資於實證醫學證據的生成，透過結合真實的世界測試和隨機對照試驗數據（重點關注安全性、治療持久性和以患者為中心的結果），預測支付方提出的問題，並加強價值對話。其次，應最佳化產品包裝選擇，使注射器和管瓶的規格與醫療服務提供者的工作流程相匹配，從而縮短給藥時間、減少浪費、簡化庫存管理並減少照護現場中的摩擦。

嚴謹的多源資訊來源方法，結合文獻綜述、相關人員訪談、細分市場分析和情境檢驗，確保獲得可操作的洞見。

本分析的調查方法結合了來自多個資訊來源的檢驗綜合和結構化的同行評審，以確保其嚴謹性和有效性。此方法首先對同行評審的臨床文獻、監管文件、安全資訊和公共更新進行全面審查，以建立關於治療概況、安全考量和監管背景的事實基礎。隨後，研究人員對包括視網膜專家、藥屋主任、醫院採購負責人、契約製造和分銷合作夥伴在內的相關人員進行了定性訪談，以了解其營運實踐和策略重點。

策略要務綜合分析強調了整合產品創新、營運、證據產生和協作獲取模式的必要性

整體而言，抗VEGF治療領域正處於一個策略曲折點，臨床預期、醫療服務創新和商業性現實正在融合，重塑醫療服務模式。持續的競爭優勢可能來自於將分子和器械層面的差異化與操作簡便性、強大的循證醫學項目以及穩健的供應鏈相結合的能力。醫療服務提供者和支付方將越來越重視已證實的患者獲益與治療營運成本之間的平衡，從而凸顯便捷的給藥方式、清晰的安全性以及可靠的供應的重要性。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 專利到期和成本壓力推動生物相似藥的廣泛應用
  • 整合人工智慧主導的影像工具以最佳化個人化VEGF療法
  • 一種新型玻璃體內給藥系統可提供緩釋性，以提高患者依從性。
  • 正在進行的臨床試驗旨在探索靶向 VEGF 和血管生成素通道的新型雙特異性抗體
  • 由於糖尿病視網膜病變發生率上升和篩檢力度加大，新興國家市場正在擴張。
  • 生技新興企業與知名製藥公司進行策略合作，開發下一代抗VEGF療法
  • 監管機構對長期生技藥品的免疫抗原性問題加強了審查
  • 成本效益分析驅動高成本生技藥品的支付方談判與報銷框架
  • 開發口服小分子 VEGF 抑制劑，旨在減少注射相關併發症
  • 採用遠距眼科平台以促進對VEGF抗治療效果的遠距監測

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依產品類型分類的抗血管內皮生長因子療法市場

  • 阿柏西普
  • Bevacizumab
  • 布羅盧西珠單抗
  • 雷珠單抗

9. 依治療領域分類的抗血管內皮生長因子療法市場

  • 老齡化黃斑部病變
  • 糖尿病黃斑部水腫
  • 近視性脈絡膜新生血管
  • 視網膜靜脈阻塞

10. 依給藥途徑分類的抗血管內皮生長因子療法市場

  • 玻璃體內注射
    • 預填充式注射器
      • 多劑量預填充
      • 單劑量預填充
    • 管瓶
      • 多劑量管瓶
      • 單劑量管瓶
  • 結膜下注射

第11章 抗血管內皮生長因子療法市場（依分銷管道分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 依最終用戶分類的抗血管內皮生長因子療法市場

  • 門診手術中心
  • 醫院
  • 眼科診所
  • 專科診所

13. 抗血管內皮生長因子療法市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 抗血管內皮生長因子療法市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國抗血管內皮生長因子療法市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • F. Hoffmann-La Roche Ltd
    • Regeneron Pharmaceuticals, Inc.
    • Bayer AG
    • Novartis AG
    • Eli Lilly and Company
    • Sanofi SA
    • Amgen Inc.
    • Pfizer Inc.
    • Viatris Inc.
    • Samsung Bioepis Co., Ltd
Product Code: MRR-B168537775F5

The Anti-vascular Endothelial Growth Factor Therapeutics Market is projected to grow by USD 18.73 billion at a CAGR of 9.57% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 9.01 billion
Estimated Year [2025] USD 9.87 billion
Forecast Year [2032] USD 18.73 billion
CAGR (%) 9.57%

Concise orientation to the evolution of anti-VEGF therapeutics and the interconnected clinical and commercial forces shaping contemporary retinal care

Anti-VEGF therapeutics have transformed the clinical management of retinal diseases, evolving from experimental biologics into foundational standards of care for conditions that threaten vision. These agents target vascular endothelial growth factor pathways to reduce pathological neovascularization and vascular leakage, thereby stabilizing or improving visual acuity for many patients. Over time, treatment paradigms have shifted from infrequent, high-burden interventions toward more patient-centric regimens that balance efficacy, safety, and dosing convenience.

Current clinical practice emphasizes personalized treatment strategies that consider lesion characteristics, disease chronicity, patient comorbidities, and adherence constraints. Advances in drug formulation and delivery platforms have introduced variations in presentation and administration that materially affect clinic workflows and procurement decisions. Concurrently, heightened scrutiny around safety signals, comparative outcomes, and value-based reimbursement is prompting manufacturers and providers to adopt more transparent evidence generation and risk-mitigation approaches.

This introduction frames the subsequent analysis by focusing on how product attributes, therapeutic indications, administration routes, distribution systems, and end-user dynamics interact to shape commercial and clinical outcomes. It also sets expectations for strategic priorities, including differentiation through dosing frequency, device format innovation, real-world evidence generation, and collaborative models between manufacturers and care providers to improve patient access and treatment continuity.

How converging clinical priorities, technological advances, and commercial pressures are redefining product value and care delivery in retinal therapeutics

The anti-VEGF landscape is undergoing transformative shifts driven by a convergence of clinical, technological, and commercial forces. Clinically, there is an intensified focus on reducing treatment burden without compromising long-term visual outcomes, which is propelling interest in agents and delivery formats that permit extended dosing intervals. Technologically, incremental innovations in formulation, molecular design, and delivery devices are enabling new value propositions centered on stability, sterility, and administration efficiency.

Commercially, payers and health systems increasingly demand robust comparative effectiveness and real-world safety data, prompting manufacturers to invest in longitudinal registries and pragmatic studies. Regulatory pathways are also evolving to address biosimilar entrants and alternative therapeutic modalities, which increases competitive pressure and encourages strategic alliances and licensing deals. In parallel, provider networks are optimizing care delivery through ambulatory surgical centers, integrated ophthalmic clinics, and specialty pharmacies that can streamline patient pathways and inventory management.

Together, these shifts are reshaping how stakeholders prioritize product attributes, contract structures, and collaboration models. Manufacturers that align molecule properties with clinician workflows, invest in post-approval evidence generation, and design flexible commercial channels will be better positioned to capture clinical momentum and sustain adoption amid intensifying competition.

Implications of recent United States tariff adjustments on supply chain resilience, sourcing strategies, and distribution planning for biologic ocular therapies

Recent tariff developments and trade policy adjustments in the United States have introduced additional variables into global supply chain planning and cost structures for biologic therapies, including anti-VEGF agents. These policy shifts have influenced strategic sourcing decisions, encouraging stakeholders to re-evaluate manufacturing footprints, regional supply redundancy, and supplier diversification to mitigate exposure to import-related cost fluctuations. Manufacturers and distributors have responded by considering onshore packaging, local fill-finish partnerships, and alternative logistics arrangements to preserve supply continuity and protect margin integrity.

For providers and pharmacies, the indirect effects of tariff-related adjustments appear in procurement negotiations, inventory strategies, and contracting terms. Procurement teams are strengthening vendor agreements to include clauses that address unexpected tariff fluctuations and are increasing collaboration with specialty distributors to align delivery schedules with clinical demand. Meanwhile, contract manufacturers and component suppliers have accelerated dialogue around qualification of secondary sources for vials, syringes, and single-use devices to reduce bottlenecks that can be exacerbated by import constraints.

Overall, these trade policy dynamics underscore the importance of supply chain resilience planning as an operational imperative. Stakeholders who proactively map their supplier ecosystems, stress-test distribution contingencies, and embed tariff sensitivity into pricing and contracting models will be better prepared to maintain access and operational stability in an uncertain trade environment.

Integrated segmentation analysis linking product attributes, indications, administration formats, distribution pathways, and care settings to strategic adoption levers

Segment-level dynamics reveal nuanced pathways to value that differ by product, indication, administration route, distribution channel, and end-user setting. Product type distinctions among aflibercept, bevacizumab, brolucizumab, and ranibizumab drive clinical positioning, safety conversations, and procurement behavior; each molecule's clinical profile informs where it will be prioritized within treatment algorithms and by payers. Therapeutic area segmentation across age related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, and retinal vein occlusion clarifies patient populations, referral pathways, and expected treatment cadence, influencing how providers select agents to balance efficacy and clinic capacity.

Route-of-administration choices shape device and workflow requirements; intravitreal injection remains the primary delivery mechanism with practical sub-segmentation into prefilled syringe and vial formats. Prefilled syringe options further divide into multi-dose prefilled and single dose prefilled presentations, while vial presentations split into multi-dose vial and single dose vial formats, each combination carrying distinct sterility, handling, and inventory implications. Subconjunctival injection represents a smaller but strategically important alternative that may be relevant for specific delivery innovations or clinical scenarios. Distribution channel distinctions among hospital pharmacies, online pharmacies, and retail pharmacies affect stocking strategies, delivery lead times, and reimbursement interactions. End-user segmentation encompassing ambulatory surgical centers, hospitals, ophthalmic clinics, and specialty clinics highlights variation in administration capacity, staffing competencies, and purchasing arrangements, which in turn informs targeted commercial engagement approaches.

Taken together, these segmentation layers create a multidimensional decision matrix for manufacturers and providers. Effective strategies will integrate product-level differentiation with tailored distribution models and end-user support programs to optimize adoption across clinical settings while addressing operational constraints related to dosing format and administration logistics.

Regional dynamics and access considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape adoption and procurement strategies

Regional dynamics are shaped by distinct regulatory regimes, care delivery infrastructures, and payer environments across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, consolidated payer negotiations and vertically integrated provider systems influence formulary placement and contracting strategies, while large tertiary centers and ambulatory surgical networks shape treatment capacity and patient throughput. Meanwhile, regulatory clarity around biosimilars and off-label use can alter competitive dynamics and procurement practices.

In Europe, Middle East & Africa, reimbursement heterogeneity and regional procurement mechanisms create differentiated pathways to market access; national health technology assessment processes and centralized tendering in some countries emphasize cost-effectiveness and comparative evidence. Provider density and the distribution of specialty clinics versus hospital-based ophthalmology services further modulate treatment accessibility. The Asia-Pacific region presents diverse market archetypes ranging from well-equipped urban centers to under-resourced rural settings, with rapid adoption in high-volume urban clinics and an increasing focus on scalable care models and local manufacturing partnerships to improve access.

Across all regions, supply chain robustness, regulatory harmonization efforts, and local clinician practice patterns will determine the pace and shape of therapeutic uptake. Stakeholders must therefore adopt regionally nuanced engagement plans that align clinical value propositions with reimbursement pathways and infrastructure realities to effectively expand access and sustain long-term adoption.

Competitive and collaborative dynamics among legacy manufacturers, biotech innovators, and service providers that define product differentiation and go-to-market success

Competitive dynamics in the space are driven by a mix of large multinational pharmaceutical companies, specialized ophthalmology companies, and biotech innovators pursuing differentiated molecular designs and delivery platforms. Legacy molecules retain a strong clinical foothold due to extensive real-world experience and established provider familiarity, while newer entrants attempt to differentiate through extended-duration efficacy, improved safety profiles, or device-enabled convenience. Concurrently, development of biosimilar and alternative biologic constructs has intensified, prompting established players to invest in lifecycle strategies, enhanced service models, and evidence generation to defend clinical position.

Partnerships and strategic alliances are increasingly common as companies seek to combine clinical development strengths with commercial reach and manufacturing capacity. Contract manufacturing organizations and specialized fill-finish partners are critical nodes in the supply chain, especially for complex biologics where sterility and cold chain integrity determine product viability. Additionally, collaboration with specialty distributors and pharmacy partners supports more efficient deployment into ambulatory surgical centers and specialty clinics, where most intravitreal administrations occur.

Investor attention and R&D investment continue to flow into formulation improvements, device innovation, and combination approaches that could alter the therapeutic calculus. Companies that align product innovation with pragmatic commercialization models, robust safety monitoring, and clinician engagement will hold an advantage in a market where clinical differentiation must be coupled with operational feasibility to achieve sustained uptake.

Practical strategic imperatives for manufacturers and providers to align clinical evidence, formats, supply resilience, and payer engagement for sustained adoption

Industry leaders should prioritize integrated strategies that align clinical differentiation with operational execution and payer engagement. First, invest in evidence generation that anticipates payer questions by combining randomized data with pragmatic real-world studies focused on safety profiles, treatment durability, and patient-centered outcomes to strengthen value conversations. Second, optimize product presentation choices by aligning syringe and vial formats with provider workflows to reduce administration time, minimize wastage, and simplify inventory management, thereby lowering friction at the point of care.

Third, build supply chain resilience through diversified sourcing, regional manufacturing partnerships, and contingency plans that account for regulatory and trade policy variability. Fourth, develop targeted distribution and contracting strategies tailored to ambulatory surgical centers, hospitals, ophthalmic clinics, and specialty clinics, recognizing that each end-user type has unique procurement cycles and clinical staffing patterns. Fifth, engage early with payers and health system formulary committees to position therapeutic value within clinical pathways and to explore outcomes-based contracting or risk-sharing arrangements where appropriate. Finally, foster collaborative clinical education programs that support safe administration practices and adherence, and leverage digital tools to improve scheduling, patient reminders, and longitudinal outcomes tracking to enhance persistence and clinic efficiency.

Rigorous, multi-source research approach combining literature synthesis, stakeholder interviews, segmentation mapping, and scenario validation to ensure actionable insights

The research methodology underpinning this analysis combined multi-source evidence synthesis with structured expert validation to ensure rigor and relevance. The approach began with a comprehensive review of peer-reviewed clinical literature, regulatory filings, safety communications, and public policy updates to establish a factual base for therapeutic profiles, safety considerations, and regulatory context. Next, qualitative interviews were conducted with a cross-section of stakeholders including retinal specialists, pharmacy directors, hospital procurement leaders, contract manufacturers, and distribution partners to surface operational realities and strategic priorities.

Data triangulation techniques were applied to reconcile divergent inputs and to contextualize claims made in isolated sources. Segmentation mapping was used to align product attributes with therapeutic indications, administration formats, distribution channels, and end-user capabilities, facilitating a multi-dimensional view of adoption drivers. Supply chain and trade policy implications were assessed through scenario analysis to identify vulnerabilities and mitigation levers. Finally, findings were synthesized into actionable recommendations and validated through follow-up consultations with clinical and commercial experts to ensure the practical applicability of the insights presented.

Synthesis of strategic imperatives emphasizing the need to integrate product innovation, operational feasibility, evidence generation, and collaborative access models

In aggregate, the anti-VEGF therapeutic area is at a strategic inflection point where clinical expectations, delivery innovations, and commercial realities converge to reshape care delivery. Sustained competitive advantage will derive from the ability to marry molecular and device-level differentiation with operational simplicity, robust evidence programs, and resilient supply chains. Providers and payers will increasingly demand alignment between demonstrated patient benefit and the operational cost of delivering therapy, which elevates the importance of dosing convenience, safety clarity, and reliable availability.

As stakeholders navigate this environment, collaboration across manufacturers, providers, distributors, and payers will become more central to improving access and optimizing outcomes. Successful strategies will balance near-term operational improvements, such as format alignment and workflow integration, with longer-term investments in evidence generation and partnership models that share risk and reward. Ultimately, the capacity to translate scientific promise into consistent real-world benefit will determine which organizations lead the next phase of retinal therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of biosimilars driven by patent expirations and cost pressures
  • 5.2. Integration of AI-driven diagnostic imaging tools to optimize VEGF therapy personalization
  • 5.3. Emerging intravitreal delivery systems offering sustained release for improved patient compliance
  • 5.4. Ongoing clinical trials exploring novel bispecific antibodies targeting VEGF and angiopoietin pathways
  • 5.5. Market expansion in emerging economies fueled by increasing diabetic retinopathy prevalence and screening initiatives
  • 5.6. Strategic partnerships between biotech startups and established pharma for next-generation anti-VEGF therapies
  • 5.7. Regulatory scrutiny intensifying around immunogenicity concerns with long-term biologic administration
  • 5.8. Cost-benefit analyses driving payer negotiations and reimbursement frameworks for expensive biologics
  • 5.9. Development of oral small-molecule VEGF inhibitors aimed at reducing injection-related complications
  • 5.10. Adoption of teleophthalmology platforms to facilitate remote monitoring of anti-VEGF treatment outcomes

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Product Type

  • 8.1. Aflibercept
  • 8.2. Bevacizumab
  • 8.3. Brolucizumab
  • 8.4. Ranibizumab

9. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Therapeutic Area

  • 9.1. Age Related Macular Degeneration
  • 9.2. Diabetic Macular Edema
  • 9.3. Myopic Choroidal Neovascularization
  • 9.4. Retinal Vein Occlusion

10. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Route Of Administration

  • 10.1. Intravitreal Injection
    • 10.1.1. Prefilled Syringe
      • 10.1.1.1. Multi Dose Prefilled
      • 10.1.1.2. Single Dose Prefilled
    • 10.1.2. Vial
      • 10.1.2.1. Multi Dose Vial
      • 10.1.2.2. Single Dose Vial
  • 10.2. Subconjunctival Injection

11. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Anti-vascular Endothelial Growth Factor Therapeutics Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Hospitals
  • 12.3. Ophthalmic Clinics
  • 12.4. Specialty Clinics

13. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche Ltd
    • 16.3.2. Regeneron Pharmaceuticals, Inc.
    • 16.3.3. Bayer AG
    • 16.3.4. Novartis AG
    • 16.3.5. Eli Lilly and Company
    • 16.3.6. Sanofi S.A.
    • 16.3.7. Amgen Inc.
    • 16.3.8. Pfizer Inc.
    • 16.3.9. Viatris Inc.
    • 16.3.10. Samsung Bioepis Co., Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AFLIBERCEPT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AFLIBERCEPT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AFLIBERCEPT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AFLIBERCEPT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY BROLUCIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY BROLUCIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY BROLUCIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY BROLUCIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RANIBIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RANIBIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RANIBIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RANIBIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MYOPIC CHOROIDAL NEOVASCULARIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MYOPIC CHOROIDAL NEOVASCULARIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MYOPIC CHOROIDAL NEOVASCULARIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MYOPIC CHOROIDAL NEOVASCULARIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MYOPIC CHOROIDAL NEOVASCULARIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MYOPIC CHOROIDAL NEOVASCULARIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MULTI DOSE PREFILLED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MULTI DOSE PREFILLED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MULTI DOSE PREFILLED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MULTI DOSE PREFILLED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MULTI DOSE PREFILLED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MULTI DOSE PREFILLED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SINGLE DOSE PREFILLED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SINGLE DOSE PREFILLED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SINGLE DOSE PREFILLED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SINGLE DOSE PREFILLED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SINGLE DOSE PREFILLED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SINGLE DOSE PREFILLED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MULTI DOSE VIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MULTI DOSE VIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MULTI DOSE VIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MULTI DOSE VIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MULTI DOSE VIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MULTI DOSE VIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SINGLE DOSE VIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SINGLE DOSE VIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SINGLE DOSE VIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SINGLE DOSE VIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SINGLE DOSE VIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SINGLE DOSE VIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SUBCONJUNCTIVAL INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SUBCONJUNCTIVAL INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SUBCONJUNCTIVAL INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SUBCONJUNCTIVAL INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SUBCONJUNCTIVAL INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SUBCONJUNCTIVAL INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY OPHTHALMIC CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY OPHTHALMIC CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY OPHTHALMIC CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY OPHTHALMIC CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA,